Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation.
Sign Up to like & getrecommendations! Published in 2022 at "International immunology"
DOI: 10.1093/intimm/dxac012
Abstract: Agonists for TLR9 and STING offer therapeutic applications both as anti-tumor agents and vaccine adjuvants, though their clinical applications are limited; the clinically available TLR9 agonist is a weak IFN inducer and STING agonists induce… read more here.
Keywords: immunity; tlr9 sting; anti tumor; sting agonists ... See more keywords